Potassium Iodide / Lugol's Solution
Brand names: Lugol's Iodine Solution (potassium iodide 10% + iodine 5%)
Potassium iodide, including as Lugol's solution, is used in thyrotoxicosis, notably to prepare patients with Graves' disease for thyroid surgery and in thyroid storm, and for thyroid blockade.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
High iodide concentrations transiently inhibit thyroid hormone release and synthesis (the Wolff-Chaikoff effect) and reduce thyroid gland vascularity, producing a rapid but temporary fall in circulating thyroid hormone.
Prescribing in practice
- The effect is transient and iodide can ultimately worsen hyperthyroidism, so it is used short term and generally after starting an antithyroid drug rather than as sole or long-term therapy.
- In thyroid storm it is given after a thionamide has been started to avoid providing fresh substrate for hormone synthesis.
- Dilute well and give orally; avoid in iodine hypersensitivity and use caution in pregnancy because iodide crosses the placenta.
Monitoring
Monitor thyroid function and clinical status, as the suppressive effect is short-lived and may escape with continued use.
Counselling the patient
- Take the diluted solution as directed, typically with or after food to reduce gastric irritation.
- Report a metallic taste, rash, swelling of the salivary glands, or worsening symptoms.
- This is a short-term treatment used as part of a wider plan for your thyroid.
Evidence & guidelines
Iodide-induced inhibition of thyroid hormone release underpins its established role in surgical preparation and thyroid storm management.
Reference: BTA Guidelines on Thyroid Storm; WHO Radiation Emergency Guidelines; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- ASA Physical Status Classification · Pre-operative Risk
- Aldrete Score for Post-Anaesthesia Discharge · Post-operative
- POSSUM Score for Surgical Morbidity and Mortality · Perioperative Risk
- Apfel Score (Post-operative Nausea and Vomiting) · PONV
- Revised Cardiac Risk Index (RCRI) · Pre-operative Risk
- Duke Activity Status Index (DASI) · Functional Assessment
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016